Is Deca‑Durabolin (nandrolone decanoate) FDA‑approved in the United States, and what are its approved indications, recommended dosing schedule, contraindications, and alternative therapies?

Deca-Durabolin (Nandrolone Decanoate): FDA Approval Status and Clinical Use

FDA Approval Status and Indication

Nandrolone decanoate is FDA-approved in the United States, but only for one specific indication: management of anemia of renal insufficiency (chronic kidney disease). 1 This represents an extremely narrow therapeutic window, and the drug is explicitly NOT approved for muscle wasting, cachexia, testosterone replacement, or performance enhancement. 2

Approved Dosing Schedule

The FDA-approved dosing for anemia of renal insufficiency is administered by deep intramuscular injection into the gluteal muscle: 1

• Women: 50-100 mg per week 1
• Men: 100-200 mg per week 1
• Children (2-13 years): 25-50 mg every 3-4 weeks 1
• Duration: Discontinue if no hematologic improvement within 6 months 1

The drug should be regarded as adjunctive therapy, requiring adequate iron intake for maximal response in anemia treatment. 1

Absolute Contraindications

Prostate cancer is an absolute contraindication, as exogenous androgen administration directly contradicts evidence-based androgen deprivation therapy, which is the cornerstone of metastatic prostate cancer management. 2

Significant cardiovascular disease represents a major contraindication, particularly given cardiovascular mortality risks. 2

Evidence Against Off-Label Uses

Cancer Cachexia and Muscle Wasting

Current guidelines explicitly recommend AGAINST routine use of nandrolone decanoate for muscle wasting conditions. 3, 4

• The ESPEN 2021 guidelines state there are "insufficient consistent clinical data to recommend currently approved androgenic steroids to increase muscle mass" in cancer patients. 3
• The ASCO 2020 guidelines found that in 37 NSCLC patients, nandrolone showed only a non-significant trend toward smaller weight loss (12% vs 25%, P=0.15). 3
• While nandrolone increased lean body mass by 1.7 kg versus 0.3 kg in placebo, it failed to improve functional outcomes including 6-minute walk distance, handgrip strength, or inspiratory pressure. 3, 4

COPD and Pulmonary Rehabilitation

The ACCP/AACVPR 2007 guidelines concluded that "current scientific evidence does not support the routine use of anabolic agents in pulmonary rehabilitation for patients with COPD" (Grade 2C recommendation). 3

Testosterone Replacement

Nandrolone is NOT appropriate for testosterone deficiency treatment—physiologic testosterone replacement is the evidence-based approach for hypogonadism. 2 The American Urological Association emphasizes that proper testosterone formulations, not anabolic steroids, should be used for hypogonadism management. 3, 2

Critical Safety Concerns

Both endogenous testosterone and gonadotropin suppression occur with nandrolone use, potentially persisting months after withdrawal. 4, 2 This represents a significant endocrine disruption that must be considered in patient selection.

Additional safety concerns include: 3, 5

• Lipid abnormalities (decreased HDL cholesterol, increased apolipoprotein B) 5
• Polycythemia 3
• Liver function abnormalities 3
• Virilization risks in women and children 4
• Cardiovascular risk requiring monitoring of blood pressure, lipid profiles, and glucose levels 2

Alternative Therapies

For Anemia in Myelofibrosis

Danazol (400-600 mg daily) may be preferable to nandrolone, with similar 35% response rate but less toxicity. 4, 2

For Cancer Cachexia

Megestrol acetate is superior to androgens for appetite stimulation and weight gain in cancer patients. 3 The combination of olanzapine plus megestrol acetate showed 85% of patients achieving ≥5% weight gain versus 41% with megestrol alone. 3

For Testosterone Deficiency

Physiologic testosterone replacement (intramuscular, transdermal patch, or transdermal gel) is the evidence-based approach, NOT anabolic steroids. 3, 2 Note that oral testosterone undecanoate is specifically contraindicated for age-related hypogonadism by the FDA. 3

Clinical Decision Algorithm

If considering nandrolone decanoate: 1

1. Confirm FDA-approved indication: Anemia of renal insufficiency only
2. Exclude absolute contraindications: Prostate cancer, significant cardiovascular disease
3. Ensure adequate iron supplementation for anemia treatment
4. Monitor response: Discontinue if no hematologic improvement within 6 months
5. Consider alternatives: Danazol for myelofibrosis-related anemia may offer better tolerability

For all other conditions (muscle wasting, cachexia, COPD, testosterone deficiency): Do not use nandrolone decanoate—evidence-based alternatives exist with superior efficacy and safety profiles. 3, 4, 2